The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010
The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010.
HIFU technology allows ambulatory treatment, ensuring it is targeted and non-operator dependent, as well as limiting the cost and the risk for the patient. EyeOP1 will be on the market in late 2010 or early 2011.
The product recently won first prize in the 2010 Innovative Medical Technology competition organized by France's Alliance for Biological and Medical Engineering (Alliance pour le Génie Biologique et Médical – AGBM). The competition is open to small and medium-sized companies developing products that have the potential to bring major advances for the healthcare system.
We were really taken with the technology developed by EyeTechCare, since it brings the hope of a solution to a worldwide public health problem, explained the President of the IMT jury, Mathias Fink, a member of the French Academy of Sciences and the Collège de France. Furthermore, EyeTechCare has succeeded in developing this device in less than two years and will soon offer medical practitioners an alternative therapeutic approach for the treatment of glaucoma.
EyeTechCare expects to confirm the preliminary results of the device’s efficacy by launching it onto the market towards the end of 2010 or early in 2011 and by embarking on a multi-center international study between 2011 and 2013. This study will enable clinical data to be acquired on a large number of patients and over a sufficient period of time.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.